Unraveling How Growth Hormone Releasing Peptides Break Down in the Body

Growth hormone releasing peptides (GHRPs) are synthetic secretagogues that stimulate the body's natural production of growth hormone (GH), impacting muscle growth, fat loss, and recovery. Peptides like GHRP-2 and ipamorelin are of particular interest in both therapeutic and anti-doping contexts. However, a comprehensive understanding of their metabolic pathways and stability in biological systems has been lacking, hindering effective detection methods and the development of more stable analogs.

The study successfully identified several major metabolites and distinct degradation pathways for both peptides. GHRP-2 exhibited rapid degradation in human plasma, demonstrating a short half-life of approximately 15 minutes, primarily due to enzymatic cleavage at the Arg-Phe bond. In contrast, ipamorelin showed significantly greater stability in plasma, with a half-life of 90 minutes, suggesting its unique N-terminal modification confers resistance to common peptidases (enzymes that break down peptides). Liver microsome incubations revealed slower degradation rates for both peptides but identified specific cytochrome P450-mediated oxidation products. > The study revealed distinct metabolic profiles, with ipamorelin demonstrating 6-fold higher stability in human plasma compared to GHRP-2, primarily due to its unique N-terminal modification. This differential stability directly impacts their in vivo pharmacokinetics and the duration they remain detectable in biological samples.